Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
217.62
-0.44 (-0.20%)
Streaming Delayed Price
Updated: 10:18 AM EDT, May 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biogen Idec
< Previous
1
2
3
4
5
6
7
8
9
...
42
43
Next >
The 3 Best Biotech Stocks to Buy Now: September 2023
September 04, 2023
With the biotech sector looking poised to continue its rally further, investors would do well to buy these stocks to capitalize.
Via
InvestorPlace
$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much Today
September 04, 2023
Via
Benzinga
(BIIB) - Analyzing Biogen's Short Interest
September 01, 2023
Via
Benzinga
Sage Therapeutics Cuts Workforce By 40% Following Rejection In Depression Treatment
August 31, 2023
The company is now focusing on its launch in postpartum depression.
Via
Investor's Business Daily
The 7 Most Promising Momentum Stocks to Own Now
August 31, 2023
These momentum stock picks are on a run, but it isn't too late to ride the rollercoaster amid broad market volatility.
Via
InvestorPlace
The 3 Most Promising Pharma Stocks to Own Now
August 30, 2023
A pillar to economic growth in a defensive area, these promising pharma stocks are set to rise and give investors one bullish ride.
Via
InvestorPlace
Analyst Ratings for Biogen
August 29, 2023
Via
Benzinga
Better Buy: Biogen vs. Eli Lilly
August 29, 2023
This battle of biotech giants has a clear winner.
Via
The Motley Fool
If You Invested $100 In This Stock 15 Years Ago, You Would Have $500 Today
August 14, 2023
Via
Benzinga
Wall Street Thinks This Tiny Biotech Company Could Soar Soon
August 28, 2023
An upcoming regulatory decision could prove to be an inflection point in the biotech's life cycle.
Via
The Motley Fool
Insider Richard Barry Just Doubled Down on Cassava (SAVA) Stock
August 24, 2023
Cassava had $168.4 million of cash at the end of June after losing $28.7 million during the second quarter of 2023. SAVA stock is up 5%
Via
InvestorPlace
Is Sage Therapeutics Stock in Trouble After Dropping 50% in a Month?
August 24, 2023
The pharmaceutical company's growth prospects have taken a big hit.
Via
The Motley Fool
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fiesta Restaurant Group, Inc. (Nasdaq - FRGI), Veritiv Corporation (NYSE - VRTV), New Relic, Inc. (NYSE - NEWR), Reata Pharmaceuticals, Inc. (Nasdaq - RETA)
August 17, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Looking Into Biogen's Recent Short Interest
August 08, 2023
Via
Benzinga
Is Sage Therapeutics a Contrarian Buy?
August 08, 2023
A regulatory setback weighed heavily on the drugmaker's shares Monday.
Via
The Motley Fool
Why Shares of Sage Therapeutics Slumped This Week
August 11, 2023
The company got bad news from the FDA and saw increased losses.
Via
The Motley Fool
Exposures
Product Safety
Could This $6.5 Billion Acquisition Help Turn Biogen's Business Around?
August 10, 2023
The company's rare disease portfolio may soon get an upgrade.
Via
The Motley Fool
With an Acquisition on the Way, Is Biogen Stock a Buy?
August 09, 2023
Can the biotech finally get back in the good graces of investors?
Via
The Motley Fool
Eli Lilly Has A Big Stake In Weight Loss And Alzheimer's Drugs; But Is The Stock A Buy?
August 09, 2023
Lilly shares surged 15% in one day to a record high. Here's what you should know.
Via
Investor's Business Daily
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: EchoStar Corporation (Nasdaq - SATS), Sovos Brands, Inc. (Nasdaq - SOVO), Reata Pharmaceuticals, Inc. (Nasdaq - RETA), Amedisys, Inc. (Nasdaq – AMED)
August 08, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
DraftKings To Rally Over 38%? Here Are 10 Other Analyst Forecasts For Tuesday
August 08, 2023
Piper Sandler raised the price target for Chegg, Inc. (NYSE: CHGG) from $11 to $13. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating. Chegg shares rose 19.9% to $12.03 in pre-market...
Via
Benzinga
What More Can Support Biogen/Sage's Zuranolone Resubmission: Analysts See Uncertain Road Ahead
August 07, 2023
The FDA approved Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc's (NASDAQ: BIIB) Zurzuvae (zuranolone) 50 mg for adults with postpartum depression (PPD) but issued a Complete Response Letter
Via
Benzinga
Dow Rises Over 300 Points To Start The Week
August 07, 2023
The Dow Jones Industrial Average was last seen up 308 points, as the blue-chip index looks to start the week on a high note following its recent losses.
Via
Talk Markets
FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says
August 07, 2023
Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q2 sales of $46.7 million, beating the consensus of $40.19 million.
Via
Benzinga
PayPal Unveils USD-Backed Stablecoin, Trucking Firm Yellow Corp Files For Bankruptcy, FDA Approves First Oral Treatment For Postpartum Depression: Today's Top Stories
August 07, 2023
Benzinga
Via
Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fiesta Restaurant Group, Inc. (Nasdaq - FRGI), Veritiv Corporation (NYSE - VRTV), New Relic, Inc. (NYSE - NEWR), Reata Pharmaceuticals, Inc. (Nasdaq - RETA)
August 07, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Why Sage Lost Half Its Value After The FDA Approved Its Depression Drug
August 07, 2023
The company gained approval for the first oral treatment for postpartum depression.
Via
Investor's Business Daily
FDA Approves Sage Therapeutics/Biogen's Zuranolone For One Type Of Depression, Rejects For Another
August 07, 2023
The FDA approved Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc's (NASDAQ: BIIB) Zurzuvae (zuranolone) 50 mg for adults with
Via
Benzinga
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
August 04, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
August 04, 2023
From
Biogen Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
42
43
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.